OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing
Moberg Pharma’s subsidiary OncoZenge has received binding undertakings regarding a directed issue of shares of SEK 10 million and a fully secured rights issue of shares of approximately SEK 60 million. The investors, which include John Fällström, Linc AB and Moberg Pharma’s largest shareholder, Östersjöstiftelsen, are subscribing for shares in the directed issue and have committed to subscribe for their parts and guarantee the remainder of the rights issue in OncoZenge.On November 6[th], 2020, Moberg Pharma announced its intention to distribute OncoZenge (“OncoZenge” or “the Company”)